Emergent BioSolutions
EBS
$3.46
Share price
-5.34%
Change (1 day)
-88.75%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Total liabilities
Total liabilities on the balance sheet as of June 2023 : $1.22 B
According to Emergent BioSolutions 's latest financial reports the company's total liabilities are $1.22 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Emergent BioSolutions - Total liabilities on balance sheet (from 2004 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $1.78 B | 33.1% |
| 2021-12-31 | $1.34 B | -6.7% |
| 2020-12-31 | $1.43 B | 15.75% |
| 2019-12-31 | $1.24 B | 1.83% |
| 2018-12-31 | $1.21 B | 671.88% |
| 2017-12-31 | $0.15 B | -57.78% |
| 2016-12-31 | $0.37 B | -2.52% |
| 2015-12-31 | $0.38 B | -2.16% |
| 2014-12-31 | $0.39 B | 185.21% |
| 2013-12-31 | $0.13 B | 12.58% |
| 2012-12-31 | $0.12 B | -6.17% |
| 2011-12-31 | $0.13 B | 2.67% |
| 2010-12-31 | $0.12 B | 25.66% |
| 2009-12-31 | $0.10 B | 10.32% |
| 2008-12-31 | $91.43 M | -10.66% |
| 2007-12-31 | $0.10 B | 2.57% |
| 2006-12-31 | $99.78 M | 145.8% |
| 2005-12-31 | $40.59 M | -11.95% |
| 2004-12-31 | $46.1 M | |
| 2002-12-31 | $18.63 M | -67.71% |
| 2001-12-31 | $57.71 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $94.38 B | 7,620.33% | 🇺🇸 USA |
 Merck MRK | $60.89 B | 4,880.86% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $59.66 B | 4,780.96% | 🇬🇧 UK |
 Soligenix SNGX | $14.48 M | -98.81% | 🇺🇸 USA |
 SIGA Technologies SIGA | $22.43 M | -98.16% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $21.77 M | -98.22% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $35.38 B | 2,794.64% | 🇮🇱 Israel |